The study for surgical outcome of trabeculectomy for neovascular glaucomatous patients who received bevacizumab treatment before the surgery.

UMIN ID: UMIN000001136

Registered date:05/05/2008

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Patients with neovascular glaucoma
• Date of first enrollment: 2008/05/01
• Target sample size: 40
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Patients are treated with an intravitreal injection of 1.25 mg bevacizumab (avastin) between 2 and 5 days before trabeculectomy, then treated with trabeculectomy.
Patients are treated with trabeculectomy without an intravitreal injection of bevacizumab (avastin).

Outcome(s)

• Primary Outcome: Intraocular pressure levels after trabeculectomy
• Secondary Outcome: Bleb formation Inflammatory reaction in anterior chamber.

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: Patients who have been previously treated with trabeculectomy. Patients who had been treated with bevacizumab within recent 2 months.

Related Information

• Primary Sponsor: Kumamoto University
• Source(s) of Monetary Support: None